Medical
-
United Therapeutics announced that its BREEZE study has demonstrated that patients with pulmonary arterial hypertension (PAH) who use Tyvaso treprostinil inhalation solution can safely switch to the Tyvaso treprostinil DPI. The company also announced that… Read more . . .
-
Meissa Vaccines said that it has started dosing participants in its Phase 2 trial of MV-012-968 intranasal live attenuated vaccine candidate against respiratory syncytial virus (RSV). MV-012-968 is based on Meissa’s AttenuBlock platform, which it… Read more . . .
-
Synairgen said that the first patient has been dosed in the Phase 3 SG018 trial of its SNG001 inhaled interferon beta-1a in hospitalized COVID-19 patients, with the SG018 study expected to enroll 610 COVID-19 patients… Read more . . .
-
A new spin out from the University of California, Davis called InVixa announced that it has acquired the rights to UC Davis intellectual property related to delivery of statins to the lung for the treatment… Read more . . .
-
Seelos Therapeutics announced that the first patients have been dosed in a Phase 2 study of its SLS-002 intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive… Read more . . .
-
Receptor Life Sciences (RLS) said that a pre-IND meeting with the FDA “resulted in clear guidance on the regulatory requirements” for development of the company’s RLS103 dry powder cannabidiol (CBD) for the treatment of panic… Read more . . .
-
According to Felix Biotechnology, Yale University researchers have initiated a Phase 1/2 trial of Felix’s YPT-01 nebulized phage therapy for the treatment of chronic P. aeruginosa infections in cystic fibrosis patients. YPT-01 was initially formulated at Yale… Read more . . .
-
Insmed announced that the first patient has been dosed in a Phase 3b trial of its Arikayce amikacin liposome inhalation suspension in patients with nontuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium complex (MAC). Arikayce is delivered… Read more . . .
-
California-based Arcturus Therapeutics announced that it will develop its ARCT-032 aerosolized CFTR mRNA formulation for the treatment of cystic fibrosis. According to Arcturus, preclinical studies of ARCT-032, which is based on the company’s LUNAR (lipid-enabled… Read more . . .
-
According to Polyphor, the UK’s MHRA has authorized a Phase 1 study of the company’s murepavadin inhalation solution, which the company is developing for the treatment of Pseudomonas aeruginosa lung infections in cystic fibrosis patients.… Read more . . .

Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
May 30-June 2: ISAM Congress 2027, Dublin, Ireland
June 23: SMI London, London, UK


